If you keep hearing about GLP-1 weight loss drugs and feel like everyone else already understands them, you're not behind. The names alone are a mess. Wegovy is an injection and also a pill now. Ozempic is the drug everyone talks about, except it's not actually approved for weight loss. Zepbound and Mounjaro are the same molecule with different labels. And since April 2026 there's a new daily pill called Foundayo.

This guide untangles all of it for a US audience: what each brand is, how these drugs work, what the trials actually showed, what you'll pay with insurance or without it, and how to track your progress without turning it into a second job.

Quick answers

• GLP-1 weight loss drugs are prescription medications that reduce appetite and slow stomach emptying. They're used alongside diet and activity changes.
• For weight loss in the US, the approved brands are Wegovy (injection and pill), Zepbound (injection), Foundayo (pill), and Saxenda (daily injection).
• Ozempic and Mounjaro are the diabetes brands of the same molecules. Doctors sometimes prescribe them off-label, but the weight loss labels belong to Wegovy and Zepbound.
• Almost nobody pays the list price. With commercial insurance and a savings card you might pay $0 to $25 a month; self-pay through LillyDirect or NovoCare runs about $149 to $449 a month as of July 2026.
• Tracking doesn't need to be perfect. Dose plus a weekly weight is a strong start, and it doubles as evidence when your insurer asks for proof the medication is working.

What are GLP-1 weight loss drugs?

GLP-1 is a hormone your gut releases after you eat. It tells your brain you're full and slows down how fast food leaves your stomach. GLP-1 drugs are lab-made versions of that signal, turned up and made to last much longer.

People say "GLP-1" like it's one drug. It's a family. The members you'll actually run into in the US:

• semaglutide (Wegovy, Ozempic, Rybelsus)
• tirzepatide (Zepbound, Mounjaro)
• orforglipron (Foundayo)
• liraglutide (Saxenda, an older once-daily injection)

Technically tirzepatide is a dual agonist (it works on GLP-1 and a second hormone signal called GIP), but everyone lumps it into the GLP-1 conversation, so we will too.

Which brand is which: the US cheat sheet

This table settles most of the confusion. When in doubt, look at the compound name in parentheses. That tells you what the medication actually is.

The Zepbound and Mounjaro split trips up almost everyone, especially anyone reading advice from abroad. In the UK, the same tirzepatide injection is sold as Mounjaro for weight loss too, which is why British articles talk about "Mounjaro for weight loss" while American ones say Zepbound. Same molecule, different label rules.

The two new pills

Until late 2025, every weight loss GLP-1 was an injection. Now there are two pills, and they're different from each other in ways that matter.

Wegovy pill (oral semaglutide 25 mg)

The FDA approved it on December 22, 2025, making it the first oral GLP-1 for weight loss. It's the same molecule as the Wegovy injection, taken as a once-daily tablet that steps up from 1.5 mg to a 25 mg maintenance dose. In the OASIS 4 trial, people who stayed on the 25 mg dose lost about 16.6% of their body weight on average over 64 weeks, which is in the same range as the weekly injection. It's a peptide, so it comes with the classic oral-semaglutide rule: take it on an empty stomach with a small amount of water, then wait before eating.

Foundayo (orforglipron)

Eli Lilly's once-daily pill, FDA-approved on April 1, 2026. It was the first new drug approved under the FDA's National Priority Voucher program, which is why it moved so fast. Unlike the Wegovy pill, orforglipron is a small molecule rather than a peptide, so it can be taken any time of day with no food or water restrictions. In its main Phase 3 obesity trial (ATTAIN-1), people who stayed on the top dose averaged about 12.4% weight loss at 72 weeks.

One correction worth making because it comes up constantly online: Foundayo is not retatrutide. Retatrutide is a separate Lilly drug, a triple agonist still in trials, not approved anywhere as of mid-2026. Anything sold online as "retatrutide" today is unapproved research-grade material, and that's a hard no for something you'd put in your body.

How they work

The simplest explanation that's still true: these drugs reduce appetite by making you feel full sooner and keeping food in your stomach longer.

Which is why people on them say things like:

• "I get full halfway through a normal plate"
• "The food noise just... stopped"
• "I walked past the pantry without thinking about it"

The changes can be subtle at first, especially at the low starter doses. That's one reason tracking helps. Your brain is terrible at remembering how hungry you used to be.

What the trials show

These numbers come from separate trials with different people, different lengths, and different designs, and some are averages for people who stayed on treatment. Treat them as rough landmarks rather than a ranking.

Two things to hold onto. First, averages hide a huge spread; some people lose far more, some far less. Second, the "best" drug on paper isn't automatically the best for you. Tolerability, price, coverage, and whether you'd rather take a daily pill or a weekly shot all count.

Insurance, prior authorization, and what you'll actually pay

The list prices are scary on purpose: roughly $1,349 a month for Wegovy and $1,086 for Zepbound. Almost nobody pays them. As of July 2026 there are four realistic ways Americans pay for these drugs.

1. Commercial insurance plus a savings card

If your plan covers the drug, the manufacturer savings card stacks on top: Wegovy as low as $0 a month, Zepbound and Foundayo as low as $25. The catch written into every card: they're for commercially insured patients only. If you're on Medicare, Medicaid, or TRICARE, you legally can't use them.

2. Prior authorization (the paperwork step)

Coverage usually isn't automatic. Your insurer will want a prior authorization (PA) from your prescriber, and some plans add step therapy, meaning you have to try a cheaper option first. PAs typically ask for your BMI history, any weight-related conditions like high blood pressure or sleep apnea, and evidence you've tried lifestyle changes. Renewals then ask whether the drug is working. This is where a clean log of your doses and weekly weights stops being a nice-to-have and becomes the document your appeal is built on.

3. Self-pay direct from the manufacturer

Both manufacturers now sell direct at cash prices that would have sounded like typos two years ago:

• Zepbound via LillyDirect: $299 a month for 2.5 mg, $399 for 5 mg, $449 for 7.5 mg and up, as single-dose vials or a KwikPen. On the 7.5 mg and higher doses, refills have to stay inside a 45-day window or the price reverts to a much higher standard rate.
• Foundayo via LillyDirect: $149 to $349 a month depending on dose, with the top doses dropping to $299 if you stay in the 45-day refill program.
• Wegovy injection via NovoCare Pharmacy: $349 a month at every standard dose, with a $199 introductory price on the first two fills of starter doses through the end of 2026.
• Wegovy pill via NovoCare: $149 for the starter dose up to $299 for the 25 mg maintenance dose. GoodRx has agreed to match these prices at retail pharmacies.

Telehealth services like Hims & Hers, Ro, Noom, and WeightWatchers Clinic now sell these same branded medications at roughly the manufacturer cash prices, bundled with their own prescribing and support fees. And a caution: mass-market compounded semaglutide and tirzepatide are effectively finished. The FDA shortages that allowed copies ended in 2024 and 2025, and copies became unlawful for compounding pharmacies after that. If someone's still offering a suspiciously cheap "compounded" version, be skeptical about what's in it.

4. Medicare and Medicaid

Medicare Part D has long excluded weight loss drugs, but from July 1, 2026 through the end of 2027 the Medicare GLP-1 Bridge changes that: eligible Part D enrollees can get Wegovy (injection or pill), Foundayo, and the Zepbound KwikPen for a flat $50 monthly copay. Those copays don't count toward your Part D deductible or the annual out-of-pocket cap, which is worth knowing when you plan your year. Medicaid coverage for obesity is still decided state by state.

Prices in this market have changed twice in the past year, so verify the current numbers on lilly.com or novocare.com before you commit to anything.

Common side effects

Most people don't quit these drugs because they "don't work". They quit because side effects made them miserable, usually during a dose increase. The common ones are stomach-related, because slowing digestion is literally how these drugs work.

Two things your care team should always know: these drugs slow stomach emptying, which matters if you're scheduled for surgery or anything involving anesthesia, and they're not recommended in pregnancy. If side effects are persistent or severe, call your prescriber rather than pushing through.

What to track in Healthcount (minimum effective tracking)

Here's what happens if you track nothing: you hit a stall week, decide the drug stopped working, forget the three good weeks before it, and start changing everything at once. Your memory is not a reliable narrator on this journey.

You don't need to log everything. Start with the level that fits your life.

Level 1: "I'm busy, but I want to start"

One US-specific bonus: if you're buying through LillyDirect self-pay, a dose log also tells you when to reorder so your refills stay inside the 45-day window that keeps the lower price on the higher doses.

Level 2: "I want better insight without obsessing"

Level 3: "I want proof, even when the scale lies"

Healthcount keeps all of this in one place: doses (weekly shots or daily pills), weight, food, measurements, and photos, so your whole journey reads as one clean timeline instead of five scattered apps.

FAQs

1) What are GLP-1 weight loss drugs?

Prescription medications that support weight loss by reducing appetite and slowing stomach emptying, used alongside diet and activity changes.

2) What's the difference between Wegovy and Ozempic?

Both are semaglutide, but Wegovy is approved for weight management and Ozempic for type 2 diabetes. If your goal is weight loss, Wegovy is the on-label option.

3) Is Zepbound the same as Mounjaro?

Same drug (tirzepatide), different labels. In the US, Zepbound covers weight loss and obstructive sleep apnea; Mounjaro covers type 2 diabetes.

4) Is Foundayo the same as retatrutide?

No. Foundayo is orforglipron, a daily GLP-1 pill approved by the FDA on April 1, 2026. Retatrutide is a different drug that's still in trials and isn't approved anywhere.

5) Pill or injection: which is better?

Whichever one you'll actually take consistently. The injections and the Wegovy pill posted the biggest trial numbers, but a daily pill you never skip beats a weekly shot you dread.

6) Will my insurance cover a GLP-1 for weight loss?

Check your plan's formulary. Many commercial plans cover at least one, usually behind a prior authorization and sometimes step therapy. With coverage plus a savings card, copays can drop to $0 to $25 a month.

7) What if my prior authorization gets denied?

Appeals succeed more often than people expect, especially with documentation: BMI history, weight-related conditions, and a dated log showing doses taken and weight change. Your prescriber's office handles the filing, but your records make their case stronger.

8) How much will I pay without insurance?

As of July 2026, roughly $149 to $449 a month buying direct from the manufacturers, depending on the drug and dose. Verify current prices on lilly.com or novocare.com because they've changed more than once this year.

9) Does Medicare cover these drugs?

The Medicare GLP-1 Bridge (July 1, 2026 through December 31, 2027) gives eligible Part D enrollees Wegovy, Foundayo, and the Zepbound KwikPen at a flat $50 monthly copay.

10) How often should I weigh myself?

Anywhere from weekly to daily works. Pick whatever keeps you consistent without stressing you out, and judge progress by the trend, not any single morning.

11) Do I need to track everything to succeed?

No. If you only log dose and weight for the first month, that's a real start, and you can build from there.